Literature DB >> 15876408

Comparative study of oestrogenic properties of eight phytoestrogens in MCF7 human breast cancer cells.

A Matsumura1, A Ghosh, G S Pope, P D Darbre.   

Abstract

Previous studies have compared the oestrogenic properties of phytoestrogens in a wide variety of disparate assays. Since not all phytoestrogens have been tested in each assay, this makes inter-study comparisons and ranking oestrogenic potency difficult. In this report, we have compared the oestrogen agonist and antagonist activity of eight phytoestrogens (genistein, daidzein, equol, miroestrol, deoxymiroestrol, 8-prenylnaringenin, coumestrol and resveratrol) in a range of assays all based within the same receptor and cellular context of the MCF7 human breast cancer cell line. The relative binding of each phytoestrogen to oestrogen receptor (ER) of MCF7 cytosol was calculated from the molar excess needed for 50% inhibition of 3H]oestradiol binding (IC50), and was in the order coumestrol (35x)/8-prenylnaringenin (45x)/deoxymiroestrol (50x)>miroestrol (260x)>genistein (1000x)>equol (4000x)>daidzein (not achieved: 40% inhibition at 10(4)-fold molar excess)>resveratrol (not achieved: 10% inhibition at 10(5)-fold molar excess). For cell-based assays, the rank order of potency (estimated in terms of the concentration needed to achieve a response equivalent to 50% of that found with 17beta-oestradiol (IC50)) remained very similar for all the assays whether measuring ligand ability to induce a stably transfected oestrogen-responsive ERE-CAT reporter gene, cell growth in terms of proliferation rate after 7 days or cell growth in terms of saturation density after 14 days. The IC50 values for these three assays in order were for 17beta-oestradiol (1 x 10(-11)M, 1 x 10(-11)M, 2 x 10(-11)M), and in rank order of potency for the phytoestrogens, deoxymiroestrol (1 x 10(-10)M, 3 x 10(-11)M, 2 x 10(-11)M)>miroestrol (3 x 10(-10)M, 2 x 10(-10)M, 8 x 10(-11)M)>8-prenylnaringenin (1 x 10(-9)M, 3 x 10(-10)M, 3 x 10(-10)M)>coumestrol (3 x 10(-8)M, 2 x 10(-8)M, 3 x 10(-8)M)>genistein (4 x 10(-8)M, 2 x 10(-8)M, 1 x 10(-8)M)/equol (1 x 10(-7)M, 3 x 10(-8)M, 2 x 10(-8)M)>daidzein (3 x 10(-7)M, 2 x 10(-7)M, 4 x 10(-8)M)>resveratrol (4 x 10(-6)M, not achieved, not achieved). Despite using the same receptor context of the MCF7 cells, this rank order differed from that determined from receptor binding. The most marked difference was for coumestrol and 8-prenylnaringenin which both displayed a relatively potent ability to displace [3H]oestradiol from cytosolic ER compared with their much lower activity in the cell-based assays. Albeit at varying concentrations, seven of the eight phytoestrogens (all except resveratrol) gave similar maximal responses to that given by 17beta-oestradiol in cell-based assays which makes them full oestrogen agonists. We found no evidence for any oestrogen antagonist action of any of these phytoestrogens at concentrations of up to 10(-6)M on either reporter gene induction or on stimulation of cell growth.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15876408     DOI: 10.1016/j.jsbmb.2004.12.041

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  25 in total

Review 1.  The life and death of breast cancer cells: proposing a role for the effects of phytoestrogens on potassium channels.

Authors:  Joanne L Wallace; Iain F Gow; Mary Warnock
Journal:  J Membr Biol       Date:  2011-07-05       Impact factor: 1.843

2.  Resveratrol rescues cAMP-dependent anionic transport in the cystic fibrosis pancreatic cell line CFPAC1.

Authors:  Nabila Hamdaoui; Maryvonne Baudoin-Legros; Mairead Kelly; Abdel Aissat; Sandra Moriceau; Diane-Lore Vieu; Julien Colas; Janine Fritsch; Aleksander Edelman; Gabrielle Planelles
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

3.  Enzyme linked immunosorbent assay for total potent estrogenic miroestrol and deoxymiroestrol of Pueraria candollei, a Thai herb for menopause remedy.

Authors:  Gorawit Yusakul; Tharita Kitisripanya; Thaweesak Juengwatanatrakul; Seiichi Sakamoto; Hiroyuki Tanaka; Waraporn Putalun
Journal:  J Nat Med       Date:  2018-02-28       Impact factor: 2.343

4.  Dietary phytoestrogen improves relaxant responses to 17-β-estradiol in aged but not ovariectomised rat bladders.

Authors:  Suzzanne J Owen; Helen M Massa; Roselyn B Rose'Meyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-06-22       Impact factor: 3.000

5.  In vitro-in silico-based analysis of the dose-dependent in vivo oestrogenicity of the soy phytoestrogen genistein in humans.

Authors:  Rungnapa Boonpawa; Albertus Spenkelink; Ans Punt; Ivonne M C M Rietjens
Journal:  Br J Pharmacol       Date:  2017-07-11       Impact factor: 8.739

6.  Inhibition of aryl hydrocarbon receptor-dependent transcription by resveratrol or kaempferol is independent of estrogen receptor α expression in human breast cancer cells.

Authors:  Laura Macpherson; Jason Matthews
Journal:  Cancer Lett       Date:  2010-09-16       Impact factor: 8.679

7.  Estrogen receptor signaling protects against immune suppression by UV radiation exposure.

Authors:  Sitarina Widyarini; Diane Domanski; Nicole Painter; Vivienne E Reeve
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-14       Impact factor: 11.205

Review 8.  Inhibition of cancer cell invasion and metastasis by genistein.

Authors:  Janet M Pavese; Rebecca L Farmer; Raymond C Bergan
Journal:  Cancer Metastasis Rev       Date:  2010-09       Impact factor: 9.264

9.  MEK4 function, genistein treatment, and invasion of human prostate cancer cells.

Authors:  Li Xu; Yongzeng Ding; William J Catalona; Ximing J Yang; Wayne F Anderson; Borko Jovanovic; Kenji Wellman; Jaqueline Killmer; Xiaoke Huang; Karl A Scheidt; R Bruce Montgomery; Raymond C Bergan
Journal:  J Natl Cancer Inst       Date:  2009-07-28       Impact factor: 13.506

Review 10.  Botanical modulation of menopausal symptoms: mechanisms of action?

Authors:  Atieh Hajirahimkhan; Birgit M Dietz; Judy L Bolton
Journal:  Planta Med       Date:  2013-02-13       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.